13744 Federal Register / Vol. 89, No. 37 / Friday, February 23, 2024 / Notices 

A. National Historic Landmarks (NHL) 

Program 

NHL Program matters will be 

considered, during which the Board 

may consider the following: 

Nominations for NHL Designation 

Commonwealth of the Northern 

Mariana Islands. 

• LATTE QUARRY AT AS NIEVES, 

Rota, CNMI. 

District of Columbia 

• THE FURIES COLLECTIVE, 

Washington, DC. 

Kentucky 

• BIG BONE LICK SITE, Union, KY. 

Nebraska 

• KREGEL WINDMILL COMPANY 

FACTORY, Nebraska City, NE. 

South Carolina 

• CHARLESTON CIGAR FACTORY, 

Charleston, SC. 

Proposed Amendments to Existing NHL 

Designations 

Alaska 

• SITKA NAVAL OPERATING BASE 

AND U.S. ARMY COASTAL DEFENSES 

(updated documentation), Sitka, AK. 

• LADD FIELD (updated 

documentation), Fairbanks, AK. 

Hawai1i 

• PU1UKOHOLA ̄ HEIAU (updated 

documentation, boundary change), 

Kawaihae, HI. 

Michigan 

• QUINCY MINING COMPANY 

HISTORIC DISTRICT (updated 

documentation, boundary change), 

Houghton County, MI. 

• CALUMET HISTORIC DISTRICT 

(updated documentation, boundary 

change), Calumet, MI. 

Missouri 

• WATKINS MILL (updated 

documentation), Lawson, MO. 

Texas 

• FORT BROWN (updated 

documentation, boundary change), 

Brownsville, TX. 

Virginia 

• CEDAR CREEK BATTLEFIELD 

AND BELLE GROVE (updated 

documentation, boundary change), 

Middletown, VA. 

Wyoming 

• WYOMING STATE CAPITOL 

BUILDING AND GROUNDS (updated 

documentation), Cheyenne, WY. 

Proposed Withdrawal of Existing 

Designations 

North Carolina 

• JOSEPHUS DANIELS HOUSE 

(WAKESTONE), Raleigh, NC. 

South Carolina 

• USS CLAMAGORE (former), Mount 

Pleasant, SC. 

B. National Natural Landmarks (NNL) 

Program 

NNL Program matters will be 

considered, during which the Board 

may consider the following: 

Nomination for NNL Designation 

Texas 

• INDEPENDENCE CREEK 

PRESERVE, Terrell County, TX. 

Interested persons may choose to 

make oral comments at the meeting 

during the designated time for this 

purpose. Depending on the number of 

people wishing to comment and the 

time available, the amount of time for 

oral comments may be limited. 

Interested parties should contact 

Monique VanLandingham (see FOR

FURTHER INFORMATION CONTACT) for 

advance placement on the public 

speaker list for this meeting. Members of 

the public may also choose to submit 

written comments by emailing them to 

monique_vanlandingham@

partner.nps.gov. Due to time constraints 

during the meeting, the Board is not 

able to read written public comments 

submitted into the record. All comments 

will be made part of the public record 

and will be electronically distributed to 

all Board members. Detailed minutes of 

the meeting will be available for public 

inspection within 90 days of the 

meeting. 

Meeting Accessibility/Special 

Accommodations: Please make requests 

in advance for sign language interpreter 

services, assistive listening devices, or 

other reasonable accommodations. We 

ask that you contact the person listed in 

the FOR FURTHER INFORMATION CONTACT

section of this notice at least seven (7) 

business days prior to the meeting to 

give the Department of the Interior 

sufficient time to process your request. 

All reasonable accommodation requests 

are managed on a case-by-case basis. 

Public Disclosure of Comments: 

Before including your address, phone 

number, email address, or other 

personal identifying information in your 

comment, you should be aware that 

your entire comment—including your 

personal identifying information—may 

be made publicly available at any time. 

While you can ask us in your comment 

to withhold your personal identifying 

information from public review, we 

cannot guarantee that we will be able to 

do so. 

Authority: 5 U.S.C. Ch. 10. 

Alma Ripps, 

Chief, Office of Policy. 

[FR Doc. 2024–03755 Filed 2–22–24; 8:45 am] 

BILLING CODE 4312–52–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–1322] 

Bulk Manufacturer of Controlled 

Substances Application: Siemens 

Healthcare Diagnostics Inc. 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Siemens Healthcare 

Diagnostics Inc. has applied to be 

registered as a bulk manufacturer of 

basic class(es) of controlled 

substance(s). Refer to SUPPLEMENTARY

INFORMATION listed below for further 

drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may submit 

electronic comments on or objections to 

the issuance of the proposed registration 

on or before April 23, 2024. Such 

persons may also file a written request 

for a hearing on the application on or 

before April 23, 2024. 

ADDRESSES: The Drug Enforcement 

Administration (DEA) requires that all 

comments be submitted electronically 

through the Federal eRulemaking Portal, 

which provides the ability to type short 

comments directly into the comment 

field on the web page or attach a file for 

lengthier comments. Please go to 

https://www.regulations.gov and follow 

the online instructions at that site for 

submitting comments. Upon submission 

of your comment, you will receive a 

Comment Tracking Number. Please be 

aware that submitted comments are not 

instantaneously available for public 

view on https://www.regulations.gov. If 

you have received a Comment Tracking 

Number, your comment has been 

successfully submitted and there is no 

need to resubmit the same comment. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.33(a), this 

is notice that on January 10, 2024, 

Siemens Healthcare Diagnostics Inc., 

100 GBC Drive, Mailstop 108, Newark, 

Delaware 19702–2461 applied to be 

registered as a bulk manufacturer of the 

following basic class(es) of controlled 

substance(s): 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 37 / Friday, February 23, 2024 / Notices 13745 

Controlled substance Drug 

code Schedule 

Ecgonine .......................... 9180 II 

The company plans to produce the 

listed controlled substance in bulk to be 

used in the manufacture of the DEA 

exempt products. No other activities for 

this drug code is authorized for this 

registration. 

Marsha Ikner, 

Acting Deputy Assistant Administrator. 

[FR Doc. 2024–03712 Filed 2–22–24; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–1323] 

Importer of Controlled Substances 

Application: Meridian Medical 

Technologies, LLC 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Meridian Medical 

Technologies, LLC has applied to be 

registered as an importer of basic 

class(es) of controlled substance(s). 

Refer to SUPPLEMENTARY INFORMATION

listed below for further drug 

information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may submit 

electronic comments on or objections to 

the issuance of the proposed registration 

on or before March 25, 2024. Such 

persons may also file a written request 

for a hearing on the application on or 

before March 25, 2024. 

ADDRESSES: The Drug Enforcement 

Administration requires that all 

comments be submitted electronically 

through the Federal eRulemaking Portal, 

which provides the ability to type short 

comments directly into the comment 

field on the web page or attach a file for 

lengthier comments. Please go to 

https://www.regulations.gov and follow 

the online instructions at that site for 

submitting comments. Upon submission 

of your comment, you will receive a 

Comment Tracking Number. Please be 

aware that submitted comments are not 

instantaneously available for public 

view on https://www.regulations.gov. If 

you have received a Comment Tracking 

Number, your comment has been 

successfully submitted and there is no 

need to resubmit the same comment. All 

requests for a hearing must be sent to: 

(1) Drug Enforcement Administration, 

Attn: Hearing Clerk/OALJ, 8701 

Morrissette Drive, Springfield, Virginia 

22152; and (2) Drug Enforcement 

Administration, Attn: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for a hearing should 

also be sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.34(a), this 

is notice that on January 17, 2024, 

Meridian Medical Technologies, LLC, 

2555 Hermelin Drive, Saint Louis, 

Missouri 63144, applied to be registered 

as an importer of the following basic 

class(es) of controlled substance(s): 

Controlled substance Drug 

code Schedule 

Morphine .......................... 9300 II 

The company plans to import the 

listed controlled substances for 

analytical purposely only. No other 

activities for these drug codes are 

authorized for this registration. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of Food and Drug 

Administration-approved or nonapproved finished dosage forms for 

commercial sale. 

Marsha Ikner, 

Acting Deputy Assistant Administrator. 

[FR Doc. 2024–03714 Filed 2–22–24; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–1318] 

Importer of Controlled Substances 

Application: Pall Life Sciences PR, LLC 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Pall Life Sciences PR, LLC has 

applied to be registered as an importer 

of basic class(es) of controlled 

substance(s). Refer to SUPPLEMENTARY

INFORMATION listed below for further 

drug information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants therefore, may submit 

electronic comments on or objections to 

the issuance of the proposed registration 

on or before March 25, 2024. Such 

persons may also file a written request 

for a hearing on the application on or 

before March 25, 2024. 

ADDRESSES: The Drug Enforcement 

Administration requires that all 

comments be submitted electronically 

through the Federal eRulemaking Portal, 

which provides the ability to type short 

comments directly into the comment 

field on the web page or attach a file for 

lengthier comments. Please go to 

https://www.regulations.gov and follow 

the online instructions at that site for 

submitting comments. Upon submission 

of your comment, you will receive a 

Comment Tracking Number. Please be 

aware that submitted comments are not 

instantaneously available for public 

view on https://www.regulations.gov. If 

you have received a Comment Tracking 

Number, your comment has been 

successfully submitted and there is no 

need to resubmit the same comment. All 

requests for a hearing must be sent to: 

(1) Drug Enforcement Administration, 

Attn: Hearing Clerk/OALJ, 8701 

Morrissette Drive, Springfield, Virginia 

22152; and (2) Drug Enforcement 

Administration, Attn: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for a hearing should 

also be sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.34(a), this 

is notice that on January 11, 2024, Pall 

Life Sciences PR, LLC, Road 194, 

Kilometer 0.4, Fajardo, Puerto Rico 

00738, applied to be registered as an 

importer of the following basic class(es) 

of controlled substance(s): 

Controlled substance Drug 

code Schedule 

Morphine .......................... 9300 II 

The company plans to import the 

listed controlled substances for research 

purposes, drug testing, and analysis to 

support foreign regulatory compliance 

of finished dosage forms to foreign 

markets. No other activities for these 

drug codes are authorized for this 

registration. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of Food and Drug 

Administration-approved or nonVerDate Sep<11>2014 17:19 Feb 22, 2024 Jkt 262001 PO 00000 Frm 00067 Fmt 4703 Sfmt 4703 E:\FR\FM\23FEN1.SGM 23FEN1

ddrumheller on DSK120RN23PROD with NOTICES1

I I 

I I 

I I